International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia

European Respiratory Journal

Volumn 50, Issue 3, 2017, Pages

  Torres, Antoni ^a   Niederman, Michael S ^b   Chastre, Jean ^c   Ewig, Santiago ^d   Fernandez Vandellos, Patricia ^e   Hanberger, Hakan ^f   Kollef, Marin ^g   Bassi, Gianluigi Li ^a   Luna, Carlos M ^h   Martin Loeches, Ignacio ^i,j   Paiva, J Artur ^k   Read, Robert C ^l   Rigau, David ^m   Timsit, Jean François ⁿ   Welte, Tobias ^o   Wunderink, Richard ^p  

^a UNIVERSITY OF BARCELONA   (Spain)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Evangelic Hospital in Herne   (Germany)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f LINKÖPING UNIVERSITY   (Sweden)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

ⁱ ST JAMES S HOSPITAL   (Ireland)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

^k University of Porto   (Portugal)

^l UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^m Iberoamerican Cochrane Centre   (Spain)

ⁿ UNIVERSITÉ PARIS DIDEROT   (France)

^o HANNOVER MEDICAL SCHOOL   (Germany)

^p NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ATRIAL NATRIURETIC FACTOR; BETA LACTAM; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CHLORHEXIDINE; COPEPTIN; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MONOCARBOXYLATE TRANSPORTER 8; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLONE DERIVATIVE; TAZOBACTAM; TOBRAMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIUM CULTURE; CLOSTRIDIUM; COST EFFECTIVENESS ANALYSIS; ENTEROBACTERIACEAE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; IMMUNE DEFICIENCY; INTERMETHOD COMPARISON; LUNG INFECTION; MEDICAL SOCIETY; METHODOLOGY; MORTALITY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PSEUDOMONAS; REVIEW; RISK REDUCTION; SEPSIS; SHORT COURSE THERAPY; STAPHYLOCOCCUS; SYSTEMATIC REVIEW; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA; DISEASE MANAGEMENT; EUROPE; INTENSIVE CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS;

CRITICAL CARE; DISEASE MANAGEMENT; EUROPE; HUMANS; PNEUMONIA, VENTILATOR-ASSOCIATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIETIES, MEDICAL;

EID: 85030025862     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00582-2017     Document Type: Review

References (133)

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
2. Craven DE, Hudcova J, Lei Y. Diagnosis of ventilator-associated respiratory infections (VARI): Microbiologic clues for tracheobronchitis (VAT) and pneumonia (VAP). Clin Chest Med 2011; 32: 547-557.
3. Rosenthal VD, Bijie H, Maki DG, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Control 2012; 40: 396-407.
4. Rosenthal VD, Maki DG, Jamulitrat S, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am J Infect Control 2010; 38: 95-104.
5. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998; 129: 433-440.
6. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122: 2115-2121.
7. Asehnoune K, Seguin P, Allary J, et al. Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe brain injury (Corti-TC): A double blind multicenter phase 3, randomised placebo-controlled trial. Lancet Respir Med 2014; 2: 706-716.
8. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31: 1312-1317.
9. Stone PW, Braccia D, Larson L. Systematic review of economic analyses of health care-associated infections. Am J Infect Control 2005; 33: 501-509.
10. Wyncoll D, Camporata L. Number needed to treat and cost-effectiveness in the prevention of ventilator-associated pneumonia. Crit Care 2012; 16: 430.
11. Erbay RH, Yalcin AN, Zencir M, et al. Costs and risks factors for ventilator-associated pneumonia in a Turkish University Hospital's Intensive Care Unit: A case-control study. BMC Pulm Med 2004; 4: 1-7.
12. Falcone M, Venditti M, Shindo Y, et al. Healthcare-associated pneumonia: Diagnostic criteria and distinction from community-acquired pneumonia. Int J Infect Dis 2011; 15: 545-550.
13. Polverino E, Torres A, Menendez R, et al. Microbial aetiology of healthcare associated pneumonia in Spain: A prospective, multicentre, case-control study. Thorax 2013; 68: 1007-1014.
14. Safdar N, Crnich CJ, Maki DG. The pathogenesis of ventilator-associated pneumonia: Its relevance to developing effective strategies for prevention. Respir Care 2005; 50: 725-739.
15. Langer M, Cigada M, Mandelli M, et al. Early onset pneumonia: A multicenter study in intensive care units. Intensive Care Med 1987; 13: 342-346.
16. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157: 531-539.
17. Martin-Loeches I, Torres A, Rinaudo M, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. J Infect 2015; 74: 213-222.
18. Martin-Loeches I, Deja M, Koulenti D, et al. Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: The interaction of ecology, shock and risk factors. Intensive Care Med 2013; 39: 672-681.
19. Ferrer M, Liapikou A, Valencia M, et al. Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit. Clin Infect Dis 2010; 50: 945-952.
20. Restrepo MI, Peterson J, Fernandez JF, et al. Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. Respir Care 2013; 58: 1220-1225.
21. Micek ST, Wunderink RG, Kollef MH, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: Impact of multidrug resistance. Crit Care 2015; 19: 219.
22. Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: Epidemiological and clinical findings. Intensive Care Med 2005; 31: 649-655.
23. Melsen WG, Rovers MM, Bonten MJ. Ventilator-associated pneumonia and mortality: A systematic review of observational studies. Crit Care Med 2009; 37: 2709-2718.
24. Bekaert M, Timsit JF, Vansteelandt S, et al. Attributable mortality of ventilator-associated pneumonia: A reappraisal using causal analysis. Am J Respir Crit Care Med 2011; 184: 1133-1139.
25. Melsen WG, Rovers MM, Koeman M, et al. Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies. Crit Care Med 2011; 39: 2736-2742.
26. Nguile-Makao M, Zahar JR, Français A, et al. Attributable mortality of ventilator-associated pneumonia: Respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models. Intensive Care Med 2010; 36: 781-789.
27. Torres A, Ewig S, Lode H. Defining, treating and preventing hospital acquired pneumonia: A European perspective. Intensive Care Med 2009; 35: 9-29.
28. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63: E61-e111.
29. Klompas M, Kleinman K, Murphy MV. Descriptive epidemiology and attributable morbidity of ventilator-associated events. Infect Control Hosp Epidemiol 2014; 35: 502-510.
30. Bouadma L, Deslandes E, Lolom I, et al. Long-term impact of a multifaceted prevention program on ventilator-associated pneumonia in a medical intensive care unit. Clin Infect Dis 2010; 51: 1115-1122.
31. Tabah A, Cotta MO, Garnacho-Montero J, et al. A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit. Clin Infect Dis 2016; 62: 1009-1017.
32. Guyatt GH, Oxman AD, Vist GE, et al. An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926.
33. Brożek JL, Akl EA, Compalati E, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy 2011; 66: 588-595.
34. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006; 355: 2619-2630.
35. Sole Violan J, Fernandez JA, Benitez AB, et al. Impact of quantitative invasive diagnostic techniques in the management and outcome of mechanically ventilated patients with suspected pneumonia. Crit Care Med 2000; 28: 2737-2741.
36. Berton DC, Kalil AC, Teixeira PJ. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database Syst Rev 2014; 10: CD006482.
37. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000; 132: 621-630.
38. Ewig S, Niederman M, Torres A. Management of suspected ventilator-associated pneumonia. Ann Intern Med 2000; 133: 1008-1009.
39. Bonten MJ, Bergmans DC, Stobberingh EE, et al. Implementation of bronchoscopic techniques in the diagnosis of ventilator-associated pneumonia to reduce antibiotic use. Am J Respir Crit Care Med 1997; 156: 1820-1824.
40. Leone M, Bourgoin A, Cambon S, et al. Empirical antimicrobial therapy of septic shock patients: Adequacy and impact on the outcome. Crit Care Med 2003; 31: 462-467.
41. Timsit JF, Harbarth S, Carlet J. De-escalation as a potential way of reducing antibiotic use and antimicrobial resistance in ICU. Intensive Care Med 2014; 40: 1580-1582.
42. Raman K, Nailor MD, Nicolau DP, et al. Early antibiotic discontinuation in patients with clinically suspected ventilator-associated pneumonia and negative quantitative bronchoscopy cultures. Crit Care Med 2013; 41: 1656-1663.
43. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated-pneumonia: Results from a large US database of culture positive pneumonia. Chest 2005; 128: 3854-3862.
44. Timsit JF. Bronchoalveolar lavage for VAP diagnosis: Patients must be sampled before any change of antimicrobial therapy. Intensive Care Med 2007; 33: 1690-1693.
45. Dennesen PJ, van der Ven AJ, Kessels AG, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163: 1371-1375.
46. Prats E, Dorca J, Pujol M, et al. Effects of antibiotics on protected specimen brush sampling in ventilator-associated pneumonia. Eur Respir J 2002; 19: 944-951.
47. Souweine B, Veber B, Bedos JP, et al. Diagnostic accuracy of protected specimen brush and bronchoalveolar lavage in nosocomial pneumonia: Impact of previous antimicrobial treatments. Crit Care Med 1998; 26: 236-244.
48. de Lassence A, Joly-Guillou ML, Salah A, et al. Accuracy of delayed (24 hours) processing of bronchoalveolar lavage for diagnosing bacterial pneumonia. Crit Care Med 2004; 32: 680-685.
49. Montravers P, Veber B, Auboyer C, et al. Diagnostic and therapeutic management of nosocomial pneumonia in surgical patients: Results of the Eole study. Crit Care Med 2002; 30: 368-375.
50. Leroy O, Jaffré S, D'Escrivan T, et al. Hospital-acquired pneumonia: Risk factors for antimicrobial-resistant causative pathogens in critically ill patients. Chest 2003; 123: 2034-2042.
51. Perbet S, Mongardon N, Dumas F, et al. Early-onset pneumonia after cardiac arrest: Characteristics, risk factors and influence on prognosis. Am J Respir Crit Care Med 2011; 184: 1048-1054.
52. Arvanitis M, Anagnostou T, Kourkoumpetis TK, et al. The impact of antimicrobial resistance and aging in VAP outcomes: Experience from a large tertiary care center. PLoS One 2014; 9: E89984.
53. Verhamme KM, De Coster W, De Roo L, et al. Pathogens in early-onset and late-onset intensive care unit-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28: 389-397.
54. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676-685.
55. Leone M, Garcin F, Bouvenot J, et al. Ventilator-associated pneumonia: Breaking the vicious circle of antibiotic overuse. Crit Care Med 2007; 35: 379-385.
56. Shindo Y, Ito R, Kobayashi D, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 2013; 188: 985-995.
57. Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc 2015; 12: 153-160.
58. Kett DH, Cano E, Quartin AA, et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: An observational, multicentre cohort study. Lancet Infect Dis 2011; 11: 181-189.
59. Torres A, Lee N, Cilloniz C, et al. Laboratory diagnosis of pneumonia in the molecular age. Eur Respir J 2016; 48: 1764-1778.
60. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237-1248.
61. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.
62. Bliziotis IA, Samonis G, Vardakas KZ, et al. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: A meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41: 149-158.
63. Koontz CS, Chang MC, Meredith JW. Effects of empiric antibiotic administration for suspected pneumonia on subsequent opportunistic pulmonary infections. Am Surg 2000; 66: 1110-1114.
64. Rello J, Ausina V, Ricart M, et al. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104: 1230-1235.
65. Aarts MA, Hancock JN, Heyland D, et al. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: A systematic review and meta-analysis of randomized trials. Crit Care Med 2008; 36: 108-117.
66. Heyland DK, Dodek P, Muscedere J, et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008; 36: 737-744.
67. Fernandez-Guerrero M, Gudiol F, Rodriguez-Torres A, et al. Nosocomial pneumonia: Comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations. Infection 1991; 19: Suppl. 6, S320-S325.
68. Jaspers CA, Kieft H, Speelberg B, et al. Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients. Antimicrob Agents Chemother 1998; 42: 1233-1238.
69. Rubinstein E, Lode H, Grassi C. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group. Clin Infect Dis 1995; 20: 1217-1228.
70. Awad S, Rodríguez AH, Chuang Y, et al. A phase randomized double blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 2014; 59: 51-61.
71. Brunkhorst FM, Oppert M, Marx G, et al. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: A randomized trial. JAMA 2012; 307: 2390-2399.
72. Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006; 1: CD003344.
73. Brusselaers N, Labeau S, Vogelaers D, et al. Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: Systematic review and diagnostic test accuracy meta-analysis. Intensive Care Med 2013; 39: 365-375.
74. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-281.
75. Chamot E, Boffi El Amari E, Rohner P, et al. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47: 2756-2764.
76. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35: 1888-1895.
77. Martinez JA, Cobos-Trigueros N, Soriano A, et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to Gram-negative microorganisms. Antimicrob Agents Chemother 2010; 54: 3590-3596.
78. Micek ST, Reichley RM, Kollef MH. Health care-associated pneumonia (HCAP): Empiric antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa predict optimal outcome. Medicine 2011; 90: 390-395.
79. Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: A retrospective analysis. Antimicrob Agents Chemother 2010; 54: 1742-1748.
80. Kumar A, Safdar N, Kethireddy S, et al. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/ meta-regression study. Crit Care Med 2010; 38: 1651-1664.
81. Kumar A, Zarychanski R, Light B, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis. Crit Care Med 2010; 38: 1773-1785.
82. Doi Y, Paterson DL. Carbapenemase-producing Enterobacteriaceae. Semin Respir Crit Care Med 2015; 36: 74-84.
83. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis 2012; 55: 943-950.
84. Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014; 20: 862-872.
85. Dimopoulos G, Poulakou G, Pneumatikos IA, et al. Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: A systematic review and meta-analysis. Chest 2013; 144: 1759-1767.
86. Pugh R, Grant C, Cooke RPD, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015; 8: CD007577.
87. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003; 290: 2588-2598.
88. Capellier G, Mockly H, Charpentier C, et al. Early-onset ventilator-associated pneumonia in adults randomized clinical trial: Comparison of 8 versus 15 days of antibiotic treatment. PLoS One 2012; 7: E41290.
89. Fekih Hassen M, Ayed S, Ben Sik Ali H, et al. Duree de l'antibiotherapie lors du traitement des pneumopathies acquises sous ventilation mecanique: Comparaison entre sept jours et dix jours. Etude pilote.[Duration of antibiotic therapy for ventilator-associated pneumonia: Comparison of 7 and 10 days. A pilot study.] Ann Fr Anesth Reanim 2009; 28: 16-23.
90. Kollef M, Chastre J, Restrepo M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012; 16: R218.
91. Medina JC, Perez Protto SE, Paciel D, et al. Antibiotic treatment for the ventilator-associated pneumonia: 8 vs. 12 days randomized trial preliminary data. Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007.
92. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162: 505-511.
93. Pugin J, Auckenthaler R, Mili N, et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143: 1121-1129.
94. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003; 31: 676-682.
95. Luyt CE, Guerin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 48-53.
96. Boeck L, Eggimann P, Smyrnios N, et al. Midregional pro-atrial natriuretic peptide and procalcitonin improve survival prediction in VAP. Eur Respir J 2011; 37: 595-603.
97. Seligman R, Seligman BGS, Teixeira PJ. Comparing the accuracy of predictors of mortality in ventilator-associated pneumonia. J Bras Pneumol 2011; 37: 495-503.
98. Seligman R, Meisner M, Lisboa TC, et al. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care 2006; 10: R125.
99. Póvoa P, Coelho L, Almeida E, et al. C-reactive protein as a marker of ventilator-associated pneumonia resolution: A pilot study. Eur Respir J 2005; 25: 804-812.
100. Tanriverdi H, Tor MM, Kart L, et al. Prognostic value of serum procalcitonin and C-reactive protein levels in critically ill patients who developed ventilator-associated pneumonia. Ann Thorac Med 2015; 10: 137-142.
101. Moreno MS, Nietmann H, Matias CM, et al. C-reactive protein: A tool in the follow-up of nosocomial pneumonia. J Infect 2010; 61: 205-201.
102. Boeck L, Eggimann P, Smyrnios N, et al. The Sequential Organ Failure Assessment score and copeptin for predicting survival in ventilator-associated pneumonia. J Crit Care 2012; 27: 523.
103. Charles PE, Tinel C, Barbar S, et al. Procalcitonin kinetics within the first days of sepsis: Relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care 2009; 13: R38.
104. Lisboa T, Seligman R, Diaz E, et al. C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumonia. Crit Care Med 2008; 36: 166-171.
105. Amour J, Bienbaum A, Langeron O, et al. Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery. Crit Care Med 2008; 36: 1147-1154.
106. Dahaba A, Rehak P, List W. Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med 2003; 29: 579-583.
107. Dahaba A, Elawady G, Rehak P, et al. Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients. Anaesth Intensive Care 2002; 30: 269-272.
108. Mongardon N, Lemiale V, Perbet S, et al. Value of procalcitonin for diagnosis of early onset pneumonia in hypothermia-treated cardiac arrest patients. Intensive Care Med 2010; 36: 92-99.
109. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial. Lancet 2010; 375: 463-474.
110. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: A randomised study. Eur Respir J 2009; 34: 1364-1367.
111. Pontet J, Paciel D, Olivera W, et al. Procalcitonin (PCT) guided antibiotic treatment in ventilator associated pneumonia (VAP). Multicentre, clinical prospective, randomized-controlled study. American Thoracic Society International Conference, San Francisco, CA, USA, 2007; A76.
112. de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial. Lancet Infect Dis 2016; 16: 819-827.
113. Heyland DK, Johnson AP, Reynolds SC, et al. Procalcitonin for reduced antibiotic exposure in the critical care setting: A systematic review and an economic evaluation. Crit Care Med 2011; 39: 1792-1799.
114. Shehabi Y, Sterba M, Garrett PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 2014; 190: 1102-1110.
115. Vidaur L, Gualis B, Rodriguez A, et al. Clinical resolution in patients with suspicion of ventilator-associated pneumonia: A cohort study comparing patients with and without acute respiratory distress syndrome. Crit Care Med 2005; 33: 1248-1253.
116. Klompas M, Speck K, Howell MD, et al. Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation: Systematic review and meta-analysis. JAMA Intern Med 2014; 174: 751-761.
117. Shi Z, Xie H, Wang P, et al. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Cochrane Database Syst Rev 2013; 8: CD008367.
118. Li J, Xie D, Li A, et al. Oral topical decontamination for preventing ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials. J Hosp Infect 2013; 84: 283-293.
119. Labeau SO, Van de Vyver K, Brusselaers N, et al. Prevention of ventilator-associated pneumonia with oral antiseptics: A systematic review and meta-analysis. Lancet Infect Dis 2011; 11: 845-854.
120. Pileggi C, Bianco A, Flotta D, et al. Prevention of ventilator-associated pneumonia, mortality and all intensive care unit acquired infections by topically applied antimicrobial or antiseptic agents: A meta-analysis of randomized controlled trials in intensive care units. Crit Care 2011; 15: R155.
121. Price R, MacLennan G, Glen J. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: Systematic review and network meta-analysis. BMJ 2014; 348: G2197.
122. Xue Y, Zhang S, Yang Y, et al. Acute pulmonary toxic effects of chlorhexidine (CHX) following an intratracheal instillation in rats. Hum Exp Toxicol 2011; 30: 1795-1803.
123. Roquilly A, Marret E, Abraham E, et al. Pneumonia prevention to decrease mortality in intensive care unit: A systematic review and meta-analysis. Clin Infect Dis 2015; 60: 64-75.
124. Daneman N, Sarwar S, Fowler RA, et al. Effect of selective decontamination on antimicrobial resistance in intensive care units: A systematic review and meta-analysis. Lancet Infect Dis 2013; 13: 328-341.
125. D'Amico R, Pifferi S, Torri V, et al. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev 2009; 4: CD000022.
126. de Smet AMGA, Kluytmans JAJW, Cooper BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009; 360: 20-31.
127. Buelow E, Gonzalez TB, Versluis D, et al. Effects of selective digestive decontamination (SDD) on the gut resistome. J Antimicrob Chemother 2014; 69: 2215-2223.
128. Oostdijk EAN, Kesecioglu J, Schultz MJ, et al. Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: A randomized clinical trial. JAMA 2014; 312: 1429-1437.
129. Oostdijk EAN, Kesecioglu J, Schultz MJ, et al. Notice of retraction and replacement: Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: A randomized clinical trial. JAMA 2017; 317: 1583-1584.
130. Oostdijk EAN, de Smet AMGA, Blok HE, et al. Ecological effects of selective decontamination on resistant Gram-negative bacterial colonization. Am J Respir Crit Care Med 2010; 181: 452-457.
131. Benus R, Harmsen H, Welling G, et al. Impact of digestive oropharyngeal decontamination on the intestinal microbiota in ICU patients. Intensive Care Med 2010; 36: 1394-1402.
132. de Smet AMGA, Hopmans TEM, Minderhoud ALC, et al. Decontamination of the digestive tract and oropharynx: Hospital-acquired infections after discharge from Intensive care unit. Intensive Care Med 2009; 35: 160-1613.
133. Branch-Elliman W, Wright SB, Howell MD. Determining the ideal strategy for ventilator-associated pneumonia prevention. Cost-benefit analysis. Am J Respir Crit Care Med 2015; 192: 57-63.